In line with these data, Shigeta et al. reported the occurrence of synergistic antitumor effects of the combination of anti-PD-1 and anti-VEGFR-2 antibodies using murine models of HCC [50]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.